Mesenchymal Cell Therapy
Mesenchymal cell therapy is regenerative medicine that involves the administration of living cells to a patient, aiming to treat or cure diseases.
Allogenic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) are capable of performing anti-inflammatory action. They can affect a variety of immune cells from inflammatory to anti-inflammatory cell types. In this example ASCs inhibit differentiation of monocytes (M0) into inflammatory macrophages (M1), while facilitating differentiation of M0 and M1 into the anti-inflammatory macrophage (M2). In addition, ASCs inhibit M0 differentiation immature dendritic cells and subsequently mature dendritic cells (imDC and DC, respectively). These immune cell types are key components in many diseases. Figure by Morten Juhl, PhD.
How Does it Work?
Mesenchymal stromal/stem cells are undifferentiated multipotent cells that reside around blood vessels in very likely all tissues of the adult body and are nature’s own efficient responders to signals triggered by tissue injury.
As a promising new therapeutic concept, pre-clinical studies and clinical trials suggest that stem cells can be used in the treatment of multiple disease conditions with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development.
Our goal is to make these mesenchymal stromal cells available for therapies as a treatment option for patients with unmet needs.
Want to Know More About our Cell Product?
Stem Cells from
Healthy Donors
Cell to Cure’s cell therapy is based on the use of mesenchymal stromal/stem cells obtained from adipose tissues donated by healthy, volunteer donors.
Adipose tissue is a rich and readily accessible source of mesenchymal stromal/stem cells, and our therapies aim to exploit the full and unique immunomodulatory and regenerative properties potentially relevant for the treatment of a variety of conditions.
Manufacturing these allogeneic adipose tissue-derived mesenchymal stromal/stem cells are off-the-shelf cell products ready to use as advanced therapy medicinal products.
Latest Publications
2025 March
Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation
Clinical
2025 March
Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial
Clinical
2024 December
Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study
Clinical
2024 June
Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia
Clinical
2024 June
Investigating the paracrine and juxtacrine abilities of adipose-derived stromal cells in angiogenesis triple cell co-cultures
Productions & Pre-clinical
2024 May
Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial
Clinical
2024 January
Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjögren’s syndrome: A randomized clinical trial
Clinical
2023 April
Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial
Clinical
2023 April
Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure
Clinical
2022 December
Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell
Productions & Pre-clinical
2022 December
Intraglandular mesenchymal stem cell treatment induces changes in the salivary proteome of irradiated patients
Clinical
2022 September
Functional in vitro models of the inhibitory effect of adipose tissue-derived stromal cells on lymphocyte proliferation: Improved sensitivity and quantification through flow cytometric analysis
Productions & Pre-clinical
2022 June
GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use
Productions & Pre-clinical
2022 June
Adipose-derived stromal cells increase the formation of collagens through paracrine and juxtacrine mechanisms in a fibroblast co-culture model utilizing macromolecular crowding
Productions & Pre-clinical
2022 May
Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II)
Clinical
2021 October
The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy
Productions & Pre-clinical
2021 January
Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease
Clinical
2020 October
Adipose Tissue-Derived Stromal Cells Induce a Highly Trophic Environment While Reducing Maturation of Monocyte-Derived Dendritic Cells
Productions & Pre-clinical
2018 July
Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate
Productions & Pre-clinical
2017 November
Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure – A Safety Study
Clinical
2017 January
Senescence and quiescence in adipose-derived stromal cells: Effects of human platelet lysate, fetal bovine serum and hypoxia
Productions & Pre-clinical
2016 November
Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture
Productions & Pre-clinical